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Imaging currently play an important role in routine clinical 
care and clinical trials in triaging patients to appropriate 
management and in monitoring patients on therapy. In terms 
of treatment assessment it is essential for imaging markers to 
be consistent, reproducible and validated. Standardized 
response assessment based on morphological change, such as 
RECIST 1.1 is well established in the clinical trial setting 
although its limitations for therapies beyond standard 
chemotherapy are recognised e.g. immunotherapy, and for 
which alternative response criteria have been proposed. 
Computed tomography (CT) remains that most commonly 
performed imaging modality due to its high spatial resolution 
and its cost-effectiveness, but positron emission tomography 
(PET) and magnetic resonance imaging (MRI) have advantages 
in their capability to image beyond morphology.  
Measurement of glucose metabolism, cell proliferation, 
hypoxia, and vascularisation is now possible in clinical 
practice as well as quantification of their spatial variation, 
providing an imaging phenotype that is likely to be more 
beneficial than simple biomarkers e.g. size in predicting 
individual patient response to therapy. These imaging 
methods can also be integrated with genomic and 
pathological data allowing a comprehensive approach to 
address the clinical need towards individualisation of therapy 
in the future.  
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In personalized medicine, early prediction of pathologic 
complete response for locally advanced rectal cancer (LARC) 
patients is essential to tailor treatment. The standard 
treatment for LARC patients consists of preoperative 
chemoradiotherapy (CRT) followed by surgery, with a 
complete response being observed in 15-30% of the patients 
after the neo-adjuvant treatment. Overtreatment of 
complete responders could be avoided if an accurate 
prediction of pCR is available, by selecting a wait-and-see 
policy instead of surgery after CRT, and thereby reducing 
treatment related complications. Further treatment 
strategies based on the prediction of pCR include a 
radiotherapy boost after CRT for patients with good response 
to achieve a higher complete response rate, and additional 
chemotherapy after initial CRT for the worst responding 
patients. 
In recent years, [18F] fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET) imaging has been 
increasingly used for decision support, treatment planning 
and response monitoring during radiotherapy. Radiomics 
(www.radiomics.org; animation: 
http://youtu.be/Tq980GEVP0Y) is a high throughput 
approach to extract and mine a large number of quantitative 
features from medical images, characterizing tumor image 
intensity, shape and texture. The core hypothesis of 
radiomics is that it can provide valuable diagnostic, 
prognostic or predictive information. FDG-PET radiomics may 
therefore facilitate early and accurate prediction of tumor 
response to treatment to identify LARC patients eligible for a 
wait and see or organ preserving approach, or patients who 
may benefit from treatment intensification. 
This presentation will focus on the methodology of, and 
technical challenges in, the development and validation of a 
predictive PET radiomic model for pCR in LARC patients, 
illustrated with recent data. 
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In vivo treatment verification is highly desirable, especially 
but not only in particle therapy where uncertainties in the 
particle range can compromise the physical advantage of this 
treatment modality. Existing measurement techniques for 
range measurements exploit physical effects, in particular 
secondary radiation that is produced by the proton beam, for 
example through activation of positron emitters, or prompt 
gamma radiation. Also biological effects caused by the 
irradiation can be used for in vivo treatment verification, if a 
functional imaging method is available to visualize the 
effect. 
One prominent example for biology-driven range verification 
is an irradiation-induced change in contrast-enhanced MRI of 
the liver. A strong systematic decrease in uptake of the 
hepatobiliary-directed contrast agent Gd-EOB-DTPA has been 
shown in irradiated healthy liver tissue 6-9 weeks after 
irradiation [1-3] using different treatment modalities 
(brachytherapy, stereotactic body radiation therapy with 
photons and protons). The underlying mechanism seems to be 
based on a pro-inflammatory reaction of the irradiated liver 
tissue resulting in a downregulation of the Gd-EOB-DTPA 
uptake transporters and an upregulation of the respective 
excretion transporters [4].  
In a prospective clinical study, carried out at Massachusetts 
General Hospital in Boston (USA), we investigated whether 
MRI of the liver can be used for in vivo dosimetric verification 
already during the course of hypo-fractionated proton 
therapy of liver metastases (5 fractions within 2 weeks). In 
contrast to the previously found late changes weeks after the 
end of treatment that were seen in all patients, for the early 
Gd-EOB-DTPA enhanced MR imaging large inter-patient 
variations were found. For 10 patients, strong or moderate 
signal changes were detected for 2 and 3 patients, 
respectively. For 5 patients no dose-correlated early signal 
change was found at all. This qualitative scoring was 
consistent with a quantitative voxelwise dose to signal 
change correlation. The analysis of additional parameters 
that could potentially explain inter-patient variations (e.g. 
dose delivered at time of MRI scans, several timing 
parameters, liver function parameters and circulating 
biomarkers of inflammation determined from blood samples 
taken before and during treatment) revealed no clear 
correlation or trend with the strength of the signal decrease. 
Hence, irradiation-induced effects in the liver can be 
detected with Gd-EOB-DTPA enhanced MRI within a few days 
after proton irradiation in a subgroup of patients. As all 
patients possessed a signal decrease in late follow up scans, 
only the early dynamics of the liver response is influenced by 
these inter-patient variations. The reason for these large 
variations in early response is not yet fully understood and 
needs further investigation.  
This presentation will cover a brief overview of biological 
effects used for treatment verification and will then focus on 
the irradiation-induced signal change in Gd-EOB-DTPA 
enhanced MRI of the liver. The hypothesis for the biological 
mechanism, the available data for late and early MRI signal 
changes will be presented and open questions will be 
discussed.  
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Debate: There are many existing IGRT options for highly 
accurate dose delivery. Is there a need for large-scale in-
room MR-guidance?  
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The statements that will be made highlighting the strong 
position we are already in when using all currently available 
advanced image-guidance strategies are used are the 
following:  
- If there is a necessity for on line MR-guidance, there is a 
general necessity for broad use of advanced image guidance 
strategies, particularly as successful screening programs such 
as those for lung cancer and potentially even pancreatic 
cancer are established, as this potentially leads to more 
localized disease being treated.  
- Several such strategies are now available but are 
underutilized, typically for lack of funding or perceived 
complexity. Recent developments such as FFF-delivery and 
fast collimators have, however, shortened a lot of treatments 
and thus rendered advanced imaging strategies more 
feasible. Considerable expertise is needed, as it is mandatory 
also for MR-guidance. 
- MR-guidance can be and has already been more easily 
applied to brachytherapy, a highly effective form of local 
therapy where technically applicable.  
- Continuous 2D-tracking based on fiducials placed in 
minimally invasive procedures has entered the clinical 
routine for the ablation of small lesions without complex 
interference of OARs.  
- 3D-imaging with CBCT, particularly in conjunction with 
breathhold strategies, still has considerable potential. 
Accuracies in the range of 3mm can be consistently achieved 
across treatment targets, in deep inspiration breathhold 
typically with very favorable dose distributions and 
straightforward dose accumulation. 4D-approaches are 
available, ultrafast "snapshot" volume imaging is ready to be 
deployed clinically. 
- Ultrasound, where applicable, allows not only for 
positioning but for tracking in 2D and 3D.  
- Surface scanning may simultaneously provide patient 
surveillance and gating signals during a therapy session.  
- Noncoplanar treatment strategies and high-LET radiation 
may have further potential to improve clinical results 
independent of imaging strategy and are currently not 
possible in conjunction with in-room MR-guidance. 
The statements suggesting that in-room MRI guidance will 
add significantly to the current armamentarium comprise 
the following: 
- Cancer is primarily a soft tissue disease. MRI offers 
unparalleled soft tissue contrast imaging across a wide range 
of cancer types and locations. In-room MRI guidance for 
cancer radiotherapy combines exquisite soft tissue imaging of 
the cancer and surrounding healthy structures with precision 
radiotherapy to optimally target the cancer and spare 
healthy tissues, affecting quality of life, cancer outcomes 
and reducing the health and economic burden of managing 
treatment-related side effects. 
- This ability to simultaneously image and target the cancer 
with radiotherapy is intuitive to patients and the treatment 
team alike. Indeed, the image quality of MRI-guidance is so 
high that a commercial online adaptive radiotherapy solution 
is only available with these systems.  
- Cancer physiology is heterogeneous and changes with time. 
MRI is the only in-room physiological targeting system for 
cancer radiotherapy. An example, tumor hypoxia, is a strong 
negative prognostic indicator of survival across a wide range 
of cancer sites, and the tumor hypoxic status changes over 
the time period of a single treatment. The ability to 
selectively image and target the most aggressive and 
resistant parts of the cancer opens up a new window to 
dramatically change cancer outcomes.  
- In addition to in-room MRI-guidance offering an improved 
treatment across a range of cancer sites, this new device also 
opens up the opportunity to explore the treatment of non-
oncologic diseases. An example is atrial fibrillation, a disease 
suffered by 6 million Europeans, with many of these patients 
treated in an invasive, long, expensive procedure. MRI-guided 
radiotherapy offers a non-invasive, short and cost-effective 
treatment of atrial fibrillation. This treatment is enabled by 
using MRI to solve the challenging problem of imaging and 
targeting small volumes affected by both respiratory and 
cardiac motion, a problem too difficult for other in-room 
imaging systems.  
- The improved outcomes and applications observed from in-
room MRI-guided radiotherapy will affect patient referral 
patterns and policy guidelines to increase the global 
radiotherapy need, benefiting the radiation oncology and 
global communities.  
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Symposium: Additional tools for contouring  
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Advances in radiotherapy delivery have been due to improved 
technique and image guidance. In contrary to the "one size 
fits it all" paradigm, personalized medicine trys to 
incorporate all available imaging information in order to 
optimally delineate the target volume. It will be highlighted, 
in how far molecular imaging such as PET has become a 
cornerstone for certain types of cancer and how PET 
information may be integrated into target delineation. 
Furthermore, it will be discussed in how far there is a role for 
a biological target volume (BTV) and how appropriate 
margins can be chosen; new tracers beyond FDG are 
discussed. The meaning of MRI and its applications as well as 
available pitfalls will be presented employing an example of 
a brain tumor treatment. 
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Significant patient anatomy changes may occur during the 
course of radiotherapy, more particularly for head and neck, 
pelvic and lung tumours. These modifications may degrade 
the plan quality over time, and hence require treatment 
adaptation based on the anatomy depicted from images of 
the treatment day.  
Any comprehensive adaptive solution will necessarily require 
automatic tools that, first, depict patients who actually need 
adaptation (dose recomputation on daily image and clinical 
indicators of plan quality), and then assist the radiation 
oncologist/therapist in the labour-intensive task of target 
volumes and organs at risk recontouring. Ultimately, this 
approach should allow treatment plan re-optimization if 
required, without unmanageable additional workload in real-
life clinical routine.  
In this framework, deformable image registration allows the 
alignment of datasets in a non-linear way, providing a voxel-
